OPTIMAS CAPITAL Ltd Sells 2,254 Shares of Eli Lilly and Company (NYSE:LLY)

OPTIMAS CAPITAL Ltd lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 13,632 shares of the company’s stock after selling 2,254 shares during the quarter. Eli Lilly and Company accounts for about 7.5% of OPTIMAS CAPITAL Ltd’s holdings, making the stock its 2nd biggest holding. OPTIMAS CAPITAL Ltd’s holdings in Eli Lilly and Company were worth $7,946,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $3,416,206,000. Moneta Group Investment Advisors LLC grew its stake in shares of Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after purchasing an additional 5,440,731 shares during the period. Morgan Stanley grew its stake in shares of Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after purchasing an additional 3,691,436 shares during the period. Imprint Wealth LLC grew its stake in shares of Eli Lilly and Company by 53,716.8% during the 2nd quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock worth $175,120,000 after purchasing an additional 1,747,946 shares during the period. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $445,944,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Truist Financial reiterated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Morgan Stanley increased their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, February 20th. Bank of America raised their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, DZ Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a report on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $689.52.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 in the last three months. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 0.0 %

NYSE LLY traded down $0.22 during trading on Thursday, hitting $777.96. The stock had a trading volume of 3,208,110 shares, compared to its average volume of 3,236,305. The company has a market capitalization of $739.19 billion, a PE ratio of 134.56, a PEG ratio of 1.70 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a 50 day moving average price of $730.97 and a 200 day moving average price of $637.01. Eli Lilly and Company has a twelve month low of $334.58 and a twelve month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.09 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 12.42 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.